Earnings Feed
Start Free
CRISPR Therapeutics AG·4

Mar 17, 5:35 PM ET

KASINGER JAMES R. 4

Research Summary

AI-generated summary

Updated

CRISPR (CRSP) General Counsel James R. Kasinger Sells 3,450 Shares

What Happened
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics (CRSP), had 6,875 restricted stock units (RSUs) vest/convert into common shares on 2026-03-14. Following that settlement, he sold 3,450 shares in an open-market transaction on 2026-03-16 at $48.26 per share, generating $166,497. The Form 4 also records the 3/14 conversion/settlement of 6,875 derivative/RSU units into shares.

Key Details

  • Transaction dates and amounts:
    • 2026-03-14: Exercise/conversion (M) / settlement of 6,875 RSUs into common shares.
    • 2026-03-16: Open-market sale (S) of 3,450 shares @ $48.26 = $166,497.
  • Shares owned after transaction: Not specified in the filing.
  • Notable footnotes:
    • F2/F4: These were RSUs (each RSU = one contingent right to a share). The award was granted 3/14/2025 for 27,500 shares with quarterly vesting; 6,875 vested 3/14/2026.
    • F3: The 3,450-share sale was required by the company’s RSU Settlement Policy to cover tax withholding and was not a discretionary trade.
    • F1: Some shares remain subject to a lock-up agreement with underwriters of the issuer’s convertible notes offering.
  • Filing: Form 4 filed 2026-03-17; no late filing is indicated in the report.

Context
The filing shows a routine RSU vest-and-settle event followed by a mandatory sell-to-cover for taxes. The M code reflects conversion/exercise of a derivative instrument (here, the RSU settlement). Because the sale was mandated for tax withholding and some shares remain locked up, this transaction should not be read as a discretionary vote of confidence or concern by the insider.